NSCLC (Issue 5) | Special Reports

IDO Inhibitors May Augment Immunotherapy in NSCLC

November 13, 2014

Clinical Articles

Combination therapies with agents such as indoleamine 2,3-dioxygenase (IDO) inhibitors may have the potential to synergize with immunotherapeutic approaches to improve immune function against tumor cells.

Early Detection and Molecular Testing Evolving for NSCLC

November 13, 2014

Clinical Articles

As with many cancers, early detection (before the onset of symptoms) offers the possibility for less expensive treatment and better outcomes in patients with non-small cell lung cancer (NSCLC).